Literature DB >> 28751311

Identification of a novel population of highly cytotoxic c-Met-expressing CD8+ T lymphocytes.

Mahdia Benkhoucha1, Nicolas Molnarfi1, Gürkan Kaya2, Elodie Belnoue3,4, Kristbjörg Bjarnadóttir1, Pierre-Yves Dietrich4, Paul R Walker4, Denis Martinvalet5, Madiha Derouazi3,4, Patrice H Lalive6,7.   

Abstract

CD8+ cytotoxic T lymphocytes (CTLs) are critical mediators of anti-tumor immunity, and controlling the mechanisms that govern CTL functions could be crucial for enhancing patient outcome. Previously, we reported that hepatocyte growth factor (HGF) limits effective murine CTL responses via antigen-presenting cells. Here, we show that a fraction of murine effector CTLs expresses the HGF receptor c-Met (c-Met+ CTLs). Phenotypic and functional analysis of c-Met+ CTLs reveals that they display enhanced cytolytic capacities compared to their c-Met- CTL counterparts. Furthermore, HGF directly restrains the cytolytic function of c-Met+ CTLs in cell-mediated cytotoxicity reactions in vitro and in vivo and abrogates T-cell responses against metastatic melanoma in vivo Finally, we establish in three murine tumor settings and in human melanoma tissues that c-Met+ CTLs are a naturally occurring CD8+ T-cell population. Together, our findings suggest that the HGF/c-Met pathway could be exploited to control CD8+ T-cell-mediated anti-tumor immunity.
© 2017 The Authors.

Entities:  

Keywords:  zzm321990CTLzzm321990; zzm321990HGFzzm321990; cancer; c‐Met; tumor immunity

Mesh:

Substances:

Year:  2017        PMID: 28751311      PMCID: PMC5579394          DOI: 10.15252/embr.201744075

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  46 in total

Review 1.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.

Authors:  F M Marincola; E M Jaffee; D J Hicklin; S Ferrone
Journal:  Adv Immunol       Date:  2000       Impact factor: 3.543

2.  A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth.

Authors:  L Trusolino; A Bertotti; P M Comoglio
Journal:  Cell       Date:  2001-11-30       Impact factor: 41.582

Review 3.  Progress in human tumour immunology and immunotherapy.

Authors:  S A Rosenberg
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

Review 4.  HGF/SF-met signaling in the control of branching morphogenesis and invasion.

Authors:  Yu-Wen Zhang; George F Vande Woude
Journal:  J Cell Biochem       Date:  2003-02-01       Impact factor: 4.429

5.  Protect the killer: CTLs need defenses against the tumor.

Authors:  Gordon J Freeman; Arlene H Sharpe; Vijay K Kuchroo
Journal:  Nat Med       Date:  2002-08       Impact factor: 53.440

Review 6.  Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Authors:  Hung T Khong; Nicholas P Restifo
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

7.  Reduced HGF expression in subcutaneous CT26 tumor genetically modified to secrete NK4 and its possible relation with antitumor effects.

Authors:  Takeshi Kubota; Hitoshi Fujiwara; Hisashi Amaike; Kazuhiro Takashima; Satoshi Inada; Kiyoto Atsuji; Mamoru Yoshimura; Kunio Matsumoto; Toshikazu Nakamura; Hisakazu Yamagishi
Journal:  Cancer Sci       Date:  2004-04       Impact factor: 6.716

8.  Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.

Authors:  Haidong Dong; Scott E Strome; Diva R Salomao; Hideto Tamura; Fumiya Hirano; Dallas B Flies; Patrick C Roche; Jun Lu; Gefeng Zhu; Koji Tamada; Vanda A Lennon; Esteban Celis; Lieping Chen
Journal:  Nat Med       Date:  2002-06-24       Impact factor: 53.440

9.  Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.

Authors:  Roberta Mortarini; Adriano Piris; Andrea Maurichi; Alessandra Molla; Ilaria Bersani; Aldo Bono; Cesare Bartoli; Mario Santinami; Claudia Lombardo; Fernando Ravagnani; Natale Cascinelli; Giorgio Parmiani; Andrea Anichini
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

10.  Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

Authors:  Willem W Overwijk; Marc R Theoret; Steven E Finkelstein; Deborah R Surman; Laurina A de Jong; Florry A Vyth-Dreese; Trees A Dellemijn; Paul A Antony; Paul J Spiess; Douglas C Palmer; David M Heimann; Christopher A Klebanoff; Zhiya Yu; Leroy N Hwang; Lionel Feigenbaum; Ada M Kruisbeek; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307

View more
  8 in total

1.  GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma.

Authors:  Manish Charan; Piyush Dravid; Maren Cam; Anthony Audino; Amy C Gross; Michael A Arnold; Ryan D Roberts; Timothy P Cripe; Alexander Pertsemlidis; Peter J Houghton; Hakan Cam
Journal:  Int J Cancer       Date:  2019-11-06       Impact factor: 7.396

2.  CD4+c-Met+Itgα4+ T cell subset promotes murine neuroinflammation.

Authors:  Mahdia Benkhoucha; Ngoc Lan Tran; Gautier Breville; Isis Senoner; Paul F Bradfield; Thalia Papayannopoulou; Doron Merkler; Thomas Korn; Patrice H Lalive
Journal:  J Neuroinflammation       Date:  2022-04-29       Impact factor: 9.587

3.  c-Met Signaling Protects from Nonalcoholic Steatohepatitis- (NASH-) Induced Fibrosis in Different Liver Cell Types.

Authors:  Hannah K Drescher; Fabienne Schumacher; Teresa Schenker; Maike Baues; Twan Lammers; Thomas Hieronymus; Christian Trautwein; Konrad L Streetz; Daniela C Kroy
Journal:  Oxid Med Cell Longev       Date:  2018-11-12       Impact factor: 6.543

4.  c-Met is expressed by highly autoreactive encephalitogenic CD8+ cells.

Authors:  Mahdia Benkhoucha; Isis Senoner; Patrice H Lalive
Journal:  J Neuroinflammation       Date:  2020-02-19       Impact factor: 8.322

5.  T-Cell Subpopulations Exhibit Distinct Recruitment Potential, Immunoregulatory Profile and Functional Characteristics in Chagas versus Idiopathic Dilated Cardiomyopathies.

Authors:  Eula G A Neves; Carolina C Koh; Thaiany G Souza-Silva; Lívia Silva Araújo Passos; Ana Carolina C Silva; Teresiama Velikkakam; Fernanda Villani; Janete Soares Coelho; Claudia Ida Brodskyn; Andrea Teixeira; Kenneth J Gollob; Maria do Carmo P Nunes; Walderez O Dutra
Journal:  Front Cardiovasc Med       Date:  2022-02-02

Review 6.  The Impact of the Epithelial-Mesenchymal Transition Regulator Hepatocyte Growth Factor Receptor/Met on Skin Immunity by Modulating Langerhans Cell Migration.

Authors:  Zsofia Sagi; Thomas Hieronymus
Journal:  Front Immunol       Date:  2018-03-16       Impact factor: 7.561

Review 7.  MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside.

Authors:  Max Hardy-Werbin; Raúl Del Rey-Vergara; Miguel Alejandro Galindo-Campos; Laura Moliner; Edurne Arriola
Journal:  Cancers (Basel)       Date:  2019-09-20       Impact factor: 6.639

8.  Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer.

Authors:  Julie E Bauman; James Ohr; William E Gooding; Robert L Ferris; Umamaheswar Duvvuri; Seungwon Kim; Jonas T Johnson; Adam C Soloff; Gerald Wallweber; John Winslow; Autumn Gaither-Davis; Jennifer R Grandis; Laura P Stabile
Journal:  Cancers (Basel)       Date:  2020-06-11       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.